Result of oversubscribed Placing and Subscription

On 12 March 2026, EnSilica plc (AIM: ENSI), a leading fabless, application-specific chipmaker, announced a proposed equity fundraising by way of an accelerated bookbuild (the "Fundraising Announcement"). The Board of EnSilica is pleased to announce that the Bookbuild has concluded and that it has conditionally raised gross proceeds of approximately £9.7 million at the Issue Price of 47 pence per share through (i) the Placing of 20,632,297 Placing Shares to new and existing institutional investors and (ii) the Subscription for 6,000 Subscription Shares.

The net proceeds of the Fundraising will enable the Company to accelerate new products and projects and its growing contract pipeline, as set out in the Fundraising Announcement.

Due to the limited existing share authorities available to issue new Ordinary Shares, the Placing will be conducted in two tranches, as follows:

• a placing of 9,660,063 Placing Shares (the "First Tranche Placing Shares") at the Issue Price, raising approximately £4.54 million, to be issued pursuant to the Company's existing authorities to issue and allot equity securities on a non-pre-emptive basis (the "First Tranche Placing"). The First Tranche Placing is conditional upon, inter alia, First Admission becoming effective on or around 17 March 2026; and
• a conditional placing of 10,972,234 Placing Shares (the "Second Tranche Placing Shares") at the Issue Price, raising approximately £5.16 million, to be issued conditional, inter alia, on the passing of the Resolutions at the General Meeting (the "Second Tranche Placing"). The General Meeting is expected to take place on 7 April 2026, notice of which will be sent to shareholders next week.

In addition to the Placing and the Subscription, the Company expects to shortly announce a separate Retail Offer through the BookBuild Platform, and this is expected to remain open until 4.00 p.m. on 17 March 2026.

The Second Tranche Placing, the Subscription and the Retail Offer (together the "Conditional Fundraising") are conditional upon, inter alia, the passing of the Resolutions to be proposed at the General Meeting to be held at the offices of Fieldfisher LLP at Riverbank House, 2 Swan Lane, London, EC4R 3TT at 10.00 a.m. on 7 April 2026 and Second Admission becoming effective on or around 8 April 2026.

A Circular, containing details of the Fundraising and the notice of General Meeting is expected to be despatched to Shareholders on or around 18 March 2026.

The Placing is also conditional on the Placing Agreement not being terminated in accordance with its terms.

Director participation

Kristoff Rademan, EnSilica's Chief Financial Officer, has conditionally subscribed for a total of 6,000 new Ordinary Shares at the Issue Price in the Subscription. On Second Admission and excluding the Retail Offer, Kristoff Rademan will hold 16,000 Ordinary Shares representing 0.014 per cent. of the enlarged issued share capital on Second Admission.

The FCA notification in respect of this director dealing, made in accordance with the requirements of UK MAR, is appended further below.

Change to significant shareholding in the Company

As a result of the issue of the First Tranche Placing Shares, the shareholding of Ian Lankshear, CEO of the Company, will be diluted on First Admission to approximately 15.10 per cent. (the number of Ordinary Shares he holds will remain the same at 16,040,358).

Admission to AIM

Application has been made to the London Stock Exchange plc for the admission of the First Tranche Placing Shares to trading on AIM and it is expected that First Admission will occur at 8.00 a.m. on or around 17 March 2026.

Application will be made to the London Stock Exchange plc for the admission of the Second Tranche Placing Shares, the Subscription Shares and the Retail Offer Shares (the "Conditional Fundraising Shares") to trading on AIM and, subject to, inter alia, approval of the Resolutions by Shareholders at the General Meeting, it is expected that Second Admission will become effective and dealings in the Conditional Fundraising Shares will commence at 8.00 a.m. on or around 8 April 2026 (or such later time and/or date as the Bookrunners and the Company may agree (being in any event no later than 8.00 a.m. on 22 April 2026)).

Total voting rights

Immediately following First Admission, the Company will have 106,260,699 Ordinary Shares of 0.1p each in issue, each with one voting right. There are no shares held in treasury. Therefore, the Company's total number of Ordinary Shares in issue and voting rights will be 106,260,699 and this figure may be used by shareholders from First Admission as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

Subject to, inter alia, the passing of the Resolutions, a further announcement will be made in due course in relation to the total number of voting rights of the Company from Second Admission.

Unless otherwise defined, definitions contained in this Announcement have the same meaning as set out in the Fundraising Announcement.

Director/PDMR MAR disclosures

Notice to Distributors

UK Product Governance Requirements

EU Product Governance Requirements

Notice to overseas persons

General

This Announcement has been issued by, and is the sole responsibility of, the Company.

Panmure Liberum, which is authorised and regulated by the FCA in the United Kingdom, is acting as Joint Broker and Bookrunner to the Company in connection with the Placing. Panmure Liberum will not be responsible to any person other than the Company for providing the protections afforded to clients of Panmure Liberum or for providing advice to any other person in connection with the Placing or any acquisition of shares in the Company. Panmure Liberum is not making any representation or warranty, express or implied, as to the contents of this Announcement. Panmure Liberum has not authorised the contents of, or any part of, this Announcement, and no liability whatsoever is accepted by Panmure Liberum for the accuracy of any information, or opinions contained in this Announcement or for the omission of any material information, save that nothing shall limit the liability of Panmure Liberum for its own fraud.